Compare Amphastar Pharmaceuticals Inc (AMPH) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Expeditors International of Wshngtn Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Expeditors International of Wshngtn Inc trades at $177.4 (market cap $23.27B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 26.9× Amphastar Pharmaceuticals Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | EXPD | |
|---|---|---|
Market Cap | $863.95M | $23.27B |
Sector | Health | Industrials |
52-Week High | $30.81 | $182.80 |
52-Week Low | $16.87 | $113.13 |
Enterprise Value | $1.26B | $22.80B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
EXPD trades at $178.71, up 0.08% on the day, with a bullish technical signal and strong recent earnings beats. The stock is near its pivot point of $179, with support at $177 and resistance at $181. Revenue grew to $11.07B in 2025, with net income of $810.33M and a robust ROE of 42.6%. Recent Q2 2026 EPS of $2.03 beat estimates by 20%, driven by airfreight and customs strength.
Outlook is mixed; strong profitability and earnings momentum support upside toward the $181.14 consensus target, but analyst sentiment is cautious with 63.6% Hold ratings. Risks include ocean freight contraction and unsustainable growth from tariff policies. The stock offers a dividend but faces macroeconomic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
